GC Biopharma's GC1126A Receives the US FDA’s Orphan Drug Designation for Thrombotic Thrombocytopenic Purpura
Shots:
- The US FDA has granted ODD to GC1126A, a novel ADAMTS13 mutein for the treatment of thrombotic thrombocytopenic Purpura (TTP)
- The non-clinical data showed the efficacy of GC1126A in disease models while maintaining higher activity levels over existing treatments or wild-type ADAMTS13, presented at ISTH 2023 Congress
- Additionally, GC1126A was designed as a modified protein that evades autoantibodies associated with the ADAMTS13 enzyme while extending its half-life. The company also focuses on providing new treatment options to patients by continuously developing innovative drugs
Ref: PR Newswire | Image: GC Biopharma
Related News:- Takeda Reports the US FDA Acceptance of BLA and Granted Priority Review of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
